Multiple System Atrophy Market on Track for Major Expansion by 2034, According to DelveInsight | Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corest

DelveInsight's "Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Multiple System Atrophy, historical and forecasted epidemiology as well as the Multiple System Atrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Multiple System Atrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple System Atrophy Market Forecast
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Multiple System Atrophy Market Report:
• The Multiple System Atrophy market size was valued approximately USD 182 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, the US held the largest market share for Multiple System Atrophy within the 7MM, valued at around USD 120 million. This figure is projected to grow further, with a compound annual growth rate (CAGR) of 3.8% by 2034
• In 2023, the US made up about 70% of the total market size within the 7MM, surpassing other major markets such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2023, Germany had the largest market size for Multiple System Atrophy among the EU countries, reaching approximately USD 7 million, while Spain had the smallest market size at around USD 4 million.
• In 2023, the estimated market size for Multiple System Atrophy in Japan was approximately USD 24 million.
• The anticipated introduction of new therapies, including Ampreloxetine (TD-9855), Lu AF82422, and ATH434, is expected to impact the total market size of MSA in the coming years.
• In July 2024, Alterity Therapeutics announced positive interim findings from the Phase II trial of ATH434 for Multiple System Atrophy. The evaluation comprised clinical and biomarker data from seven participants who were treated for six months, and neuroimaging data from three participants treated for 12 months. Remarkably, 43% of the participants showed improved scores on the UMSARS Activities of Daily Living Scale after six months, indicating a potential decrease in disability.
• According to DelveInsight's analysis, the US had the highest number of diagnosed prevalent cases of Multiple System Atrophy in 2023 among the 7MM, with approximately 24,500 cases. This number is expected to rise by 2034.
• In the US in 2023, the diagnosed prevalent cases by age group were approximately 300 for ages 30-39, around 4,300 for ages 40-49, about 11,200 for ages 50-59, nearly 6,400 for ages 60-79, and approximately 2,300 for those aged 80 and above.
• In Europe, Germany had the highest number of diagnosed prevalent cases of Dementia, totaling around 3,800. Among these, males were more affected, accounting for approximately 2,100 cases, while females had around 1,700 cases.
• The US recorded approximately 17,600 cases of MSA-P and around 6,800 cases of MSA-C. These numbers are expected to grow during the forecast period from 2024 to 2034, indicating a projected rise in the prevalence of both forms of Multiple System Atrophy.
• Key Multiple System Atrophy Companies: Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others
• Key Multiple System Atrophy Therapies: Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, Verdiperstat, TAK-341, KM-819, rasagiline mesylate, Safinamide Methanesulfonate, AZD3241, NBMI, hOMSC300, DaTSCAN™ Ioflupane, Droxidopa, and others
• The Multiple System Atrophy epidemiology based on gender analyzed that males are most commonly affected as compare females in case of Multiple System Atrophy (MSA) in the 7MM
• The Multiple System Atrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple System Atrophy pipeline products will significantly revolutionize the Multiple System Atrophy market dynamics.

Multiple System Atrophy Overview
Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects the body's autonomic functions, such as blood pressure, heart rate, bladder function, and digestion, as well as motor control. MSA is characterized by a combination of symptoms similar to those of Parkinson's disease, cerebellar ataxia, and autonomic failure.

Get a Free sample for the Multiple System Atrophy Market Report:
https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple System Atrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Multiple System Atrophy Epidemiology Segmentation:
The Multiple System Atrophy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Multiple System Atrophy
• Prevalent Cases of Multiple System Atrophy by severity
• Gender-specific Prevalence of Multiple System Atrophy
• Diagnosed Cases of Episodic and Chronic Multiple System Atrophy

Download the report to understand which factors are driving Multiple System Atrophy epidemiology trends @ Multiple System Atrophy Epidemiology Forecast
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple System Atrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple System Atrophy market or expected to get launched during the study period. The analysis covers Multiple System Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Multiple System Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Multiple System Atrophy Therapies and Key Companies
• Lu AF82422: H Lundbeck A/S
• Ampreloxetine (TD-9855): Theravance Biopharma
• AAV2-GDNF Gene Therapy: Brain Neurotherapy Bio, Inc
• ION464: Ionis Pharmaceuticals, Inc.
• ATH434: Alterity Therapeutics
• Verdiperstat: Biohaven Pharmaceuticals, Inc.
• TAK-341: Takeda
• KM-819: Kainos Medicine Inc.
• rasagiline mesylate: Teva Branded Pharma
• Safinamide Methanesulfonate: Zambon SpA
• AZD3241: AstraZeneca
• NBMI: EmeraMed
• hOMSC300: Cytora Ltd.
• DaTSCAN™ Ioflupane: GE Healthcare
• Droxidopa: Chelsea Therapeutics

Discover more about therapies set to grab major Multiple System Atrophy market share @ Multiple System Atrophy Treatment Market
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple System Atrophy Market Drivers
• Prospect for a robust pipeline
• New Pre-clinical MoAs
• Increase in Multiple System Atrophy research
• Regulatory designations

Multiple System Atrophy Market Barriers
• Launch of generics
• Diagnostic barrier
• Limited clinical research

Scope of the Multiple System Atrophy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Multiple System Atrophy Companies: Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others
• Key Multiple System Atrophy Therapies: Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, Verdiperstat, TAK-341, KM-819, rasagiline mesylate, Safinamide Methanesulfonate, AZD3241, NBMI, hOMSC300, DaTSCAN™ Ioflupane, Droxidopa, and others
• Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies
• Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Multiple System Atrophy Unmet Needs, KOL's views, Analyst's views, Multiple System Atrophy Market Access and Reimbursement

To know more about Multiple System Atrophy companies working in the treatment market, visit @ Multiple System Atrophy Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Multiple System Atrophy Market Report Introduction
2. Executive Summary for Multiple System Atrophy
3. SWOT analysis of Multiple System Atrophy
4. Multiple System Atrophy Patient Share (%) Overview at a Glance
5. Multiple System Atrophy Market Overview at a Glance
6. Multiple System Atrophy Disease Background and Overview
7. Multiple System Atrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Multiple System Atrophy
9. Multiple System Atrophy Current Treatment and Medical Practices
10. Multiple System Atrophy Unmet Needs
11. Multiple System Atrophy Emerging Therapies
12. Multiple System Atrophy Market Outlook
13. Country-Wise Multiple System Atrophy Market Analysis (2020-2034)
14. Multiple System Atrophy Market Access and Reimbursement of Therapies
15. Multiple System Atrophy Market Drivers
16. Multiple System Atrophy Market Barriers
17. Multiple System Atrophy Appendix
18. Multiple System Atrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Multiple System Atrophy Pipeline https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Multiple System Atrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Multiple System Atrophy market. A detailed picture of the Multiple System Atrophy pipeline landscape is provided, which includes the disease overview and Multiple System Atrophy treatment guidelines.

Multiple System Atrophy Epidemiology https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Multiple System Atrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Multiple System Atrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Congestive Heart Failure Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical and forecasted epidemiology as well as the CHF market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

CDMO Market
https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market
Global CDMO market was valued at USD 100.02 billion in 2021, growing at a CAGR of 6.25% during the forecast period from 2024 to 2030, in order to reach USD 143.87 billion by 2030. Factors such as rising prevalence of various chronic and acute diseases leading to growing requirement of drugs, rising popularity of biologics as a treatment option are further expected to drive the demand for services offered by CDMOs as biologics being more complex than small molecules require elaborate facilities for product development.

Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
DelveInsight's "Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Duchenne Muscular Dystrophy historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Generalized Myasthenia Gravis Market
https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market
DelveInsight's 'Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Generalized Myasthenia Gravis, historical and forecasted epidemiology as well as the market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.